Treatment with a neutralizing anti-GPR77 antibody suppresses the activity of NF-κB, IL-6, and IL-8 secretion, abolishes establishment of breast cancer patient-derived xenograft in the immunocompromised mice, and restores docetaxel chemosensitivity [45]. This evidence concerns the gene C5AR2 and breast cancer.